This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...
-
Investigations into Differences between Vaccinia and Myxoma Virus Plaquing Properties Identifies Strategies for Increasing the Oncolytic Efficacy of Myxoma Virus
DownloadFall 2013
Despite both being poxviruses, vaccinia (VACV) and myxoma (MYXV) form very different plaque types. VACV plaques are large and show a central clearing of cells, while MYXV plaques are smaller and result in a clumping of cells. VACV spread is promoted by the formation of an enveloped form of virus...